Core Insights - NeuroPace, Inc. announced three-year effectiveness data from the Post-Approval Study (PAS) of the RNS® System, showing an 82% median reduction in seizures for adults with drug-resistant focal epilepsy [1][6][7] - The data was presented at the American Academy of Neurology (AAN) Annual Meeting, highlighting the RNS System as the only FDA-approved device providing brain-responsive neurostimulation [2][3] Company Overview - NeuroPace is a medical device company focused on improving the lives of individuals with epilepsy through innovative solutions [5] - The RNS System is the first commercially available platform that delivers personalized, real-time treatment at the seizure source [5] Clinical Study Details - The PAS enrolled 324 patients across 32 centers, making it the largest FDA-reviewed, prospectively enrolled trial in neuromodulation for drug-resistant focal epilepsy [2][3] - The three-year effectiveness analysis indicated that 42% of patients remained seizure-free for over six months [6][7] Treatment Efficacy - The RNS System demonstrated a median seizure reduction of 62% at six months and 82% at three years [6][7] - The device provides greater seizure reduction compared to other neuromodulation therapies and is designed to offer personalized treatment [2][3]